Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (May 2026)
28 slides from Sona Nanotech's investor presentation, May 2026
Slide 1: Sona's 'Targeted Hyperthermia Therapy': The Clinical Promise of THT
Sona’s ‘Targeted Hyperthermia Therapy’: Realizing The Full Potential of Immunotherapy: The Clinical Promise of THT May, 2026 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses activities this presentation due to risks and uncertainties affecting Sona or developments tha
Slide 3: Executive Summary
Executive Summary • Sona’s gentle and biocompatible therapy ‘primes’ tumors immunogenically so they respond to immunotherapy cancer drugs • Potential to significantly raise current immunotherapy drugs response rates from ~21% average • Sona's therapy primed 8 of 10 biopsied tumors in patients who ha
Slide 4: Immunotherapy Was A 2011 Breakthrough in Cancer Care
Immunotherapy Was A 2011 Breakthrough in Cancer Care… But Its Full Promise Is Unfulfilled Efficacy in Melanoma Efficacy by Cancer Type Opportunity for Improvement JAMA Oncol . 2021 May 1;7(5):739-743. 4
Slide 5: Only 34% of People With Stage IV Melanoma Live Past Five Years
As A Result, Only 34% People With Stage IV Melanoma Can Expect To Live Past Five Years Notes: 1) In a study of overall survival in advanced melanoma 2) Patients treated with anti–programmed cell death 1 or programmed cell death ligand-1 immunotherapy Sources: Melanoma Volume 30, Issue 4 p582-588; CA
Slide 6: For Those Who Respond To Immunotherapy, Chronic Toxicity Typically Ensues
For Those Who Do Respond To Immunotherapy, Chronic Toxicity Typically Ensues 15% – 20% Grade III or higher toxicity with single agent PD-1 immunotherapy and up to 60% when combined with CTLA-4(1) Making immunotherapy work more often while also limiting its side effects would represent a transformati
Slide 7: Immunotherapy Response Rates Are Low Because Tumor Antigens Are Too Weak
Immunotherapy Response Rates Are Low Because Tumor Antigens Presented Are Too Weak To Elicit An Immune Response Sources of Immunotherapy Resistance 1. Weak tumor antigen expression 2. Upregulation of immune-checkpoint molecules (immune fatigue) 3. Activation of alternative signaling pathways 4. Immu
Slide 8: Targeted Hyperthermia Therapy Converts Immune 'Cold' Melanoma
Targeted Hyperthermia Therapy (THT) Converts Immune ‘Cold’ Melanoma Into A Systemically Responsive Disease 8
Slide 9: THT Uses Sona's Biocompatible Gold Nanorods
THT Uses Sona’s Biocompatible Gold Nanorods Which Are Fastest To Convert Light Energy To Heat Tumors From The Inside, Out Sona’s Gold Nanorod’s (“GNR”) Advantages Highly functional: • Optimal nanoparticle for thermal conversion • Can be ‘tuned’ to react to set wavelengths • Can be conjugated to mole
Slide 10: Heating Tumors Sub-ablatively Reveals New Signals That Engage the Immune System
Heating Tumors Sub-ablatively Selectively Kills Cancer Cells And Reveals New Signals That Cause The Immune System To Engage Targeted Hyperthermia Therapy (“THT”) • Near Infrared (NIR) light (860 nanometers) • Aimed at…. • 60 x 15 nanometer gold nanorods (GNRs) • Produces….. • Controllable ~44°C “hyp
Slide 11: THT Involves In-clinic Injection Of Gold Nanorods Followed By Near Infrared Light
THT Involves In-clinic Injection Of Biocompatible Sona Gold Nanorods Into A Tumor Followed By A 5-10 Minute Application Of Near Infrared Light Step 1 - Intertumoral injection of 0.5ml Step 2 - Initiate and monitor GNR solution hyperthermia for 5-10 minutes 11
Slide 12: Malignant Tumors Biopsied Negative For Cancer Within Two Weeks
Malignant Tumors Biopsied Negative For Cancer Within Two Weeks, With Secondary, ‘Abscopal Effect’ Also Demonstrated Day 1 - Pre-THT Day 16 - After THT x2 Tumors Abscopal effect treated seen as untreated with THT tumors improved 12
Slide 13: THT's First-in-human Clinical Study As A Monotherapy
THT’s First-in-human Clinical Study As A Monotherapy Demonstrated Safety, Tolerability, Efficacy And Abscopal Effect Primary Objectives • Safety: No serious adverse events related to the therapy • Tolerability: No drop-outs and no refusals to second treatment • Device design: 16+ technique and devic
Slide 14: Sona's First-In-Human Clinical Study Generated Important Insights
Sona’s First-In-Human Clinical Study Generated Important Insights 1. THT primes tumors immunogenically 2. THT’s ‘hyperthermia’ heat of ~44°C is correct 3. Five-minute treatment is sufficient 4. THT alone (x2) eliminated the cancer in many tumors in two weeks 5. No tumor re-growth seen in several pat
Slide 15: Sona's Clinical Strategy Seeks To Answer Further Questions
Based On This Success, Sona’s Clinical Strategy Seeks To Answer Further Questions To Inform Its Regulatory Approval Applications 1. Will THT with immunotherapy as a combination therapy be safe for human patients? 2. Will a combination THT + immunotherapy treatment be tolerable by human patients? 3.
Slide 16: THT With Immunotherapy In A Preclinical Colorectal Cancer Study
Sona Showed That THT With Immunotherapy Can Unlock Its Full Potential To Suppress Tumor Growth In A New Preclinical Colorectal Cancer Study Published April 6, 2026 38% of combination therapy cohort showed treatment durability to day 48 16 Source: https://link.springer.com/article/10.1186/s12951-026-
Slide 17: The IGNITE-THT Study Will Generate Insights On A THT Plus Immunotherapy Combination
The IGNITE-THT Study Will Generate Insights On A THT Plus Immunotherapy Combination, Potentially Setting A New Standard For Efficacy And Tolerability In Melanoma Treatment Stage: Stage 0/I Stage II Stage III Stage IV Resection Resectable: Surgery before or (2A) after systemic immunotherapy Current S
Slide 18: The IGNITE-THT Study Will Assess The Combination Therapy Against Two Alternatives
The IGNITE-THT Study Will Assess The Combination Therapy’s Performance Relative To Two Alternatives Early Feasibility Study Protocol (Select Stage III and IV Melanoma Patients, n=30) Arm 1 – IL-2 intratumorally (n=10) (Standard of Care) Eligibility Standard Arm 2 – THT + IL-2 intratumorally Screen P
Slide 19: IGNITE-THT Will Address The Worst Late-stage Cases
IGNITE–THT Will Address The Worst Late-stage Cases But Could THT Be Used To Catch The Cancer Before It Spreads In Much Larger Group Affected In Earlier Stages? 96,790 Stage 0, I & II New Melanoma Cases Patients Each Year: 10,601 Stage III Patients 4,609 Stage IV Patients Source: US 2026 estimates fr
Slide 20: Sona's PRIME-THT Study Will Look At Earlier Stage Cases
Sona’s PRIME-THT Study (Precision Regional Immunotherapy For Melanoma Enhanced By THT) Will Look At Earlier Stage Cases Stage: Stage 0/I Stage II Stage III Stage IV Resection Resectable (2A) Current Surgical Resection Standards of Immunotherapy Care: with surgery Unresectable: Immunotherapy (2C) Fut
Slide 21: The PRIME-THT Study Will Assess THT + Immunotherapy Up-front
The PRIME-THT Study Will Assess THT + Immunotherapy Up- front To Prevent Spread and Recurrence from Early-Stage Disease Early Feasibility Study Protocol (Select Stage II and III Newly Diagnosed Melanoma Patients, n=10) THT + IL-2 +CTLA-4 Day 42 Eligibility PD-1 immunotherapy intratumorally (n=10) St
Slide 22: IGNITE-THT and PRIME-THT Could Help The Growing Number Diagnosed With Melanoma
IGNITE-THT and PRIME-THT Studies Could Lead To Helping The Growing Number Of People Who Will Be Diagnosed With Melanoma 22 Source: International Agency For Research On Cancer (https://gco.iarc.who.int/today/home)
Slide 23: Sona's Product Pipeline – By Stage Of Development
Sona Intends To Leverage Its Uniquely Biocompatible GNR Platform Technology To Develop Further Applications Sona’s Product Pipeline – By Stage Of Development TARGET OR DISCOVERY & PRE-CLINICAL EARLY PROGRAM INDICATION FEASIBILITY PILOT PIVOTAL APPROVED DESCRIPTION CONCEPT DESIGN STUDIES Melanoma Sta
Slide 24: Sona's THT Therapy Is Proprietary And Benefits From IP Protection
Sona’s THT Therapy Is Proprietary And Benefits From IP Protection Sona’s IP Advantages Patents: THT Theragnostic concept: • Method for Manufacture of Biocompatible Gold Nanorods • Leveraging both the biocompatibility and • Issued: USA, Canada and South Korea. Pending: PCT, EU. functionality of Sona’
Slide 25: Path Forward
Path Forward 1. Publish first-in-human results showing THT alone priming tumors • Then tell the world at ASCO on May 30th 2. Two ‘combination’ clinical studies with early read-outs expects in Q4 2026 • THT + immunotherapy for late-stage melanoma to show durability • THT + immunotherapy for early-sta
Slide 26: Sona's Team Hits Above The Company's Weight
Sona’s Team Hits Above The Company’s Weight Board Mark Lievonen, C.M. Walter Strapps PhD Neil Fraser, P.Eng., MBA Jim Megann Wayne Myles, KC Chairman Director Len Pagliaro, PhD Director Director Director Director o Led vaccine maker Sanofi- o CSO of Khosla Ventures o Led Medtronic Canada o 25 years
Slide 27: Capitalization Table
Capitalization Table As of May 13, 2026 Market Capitalization Ownership Share Price C$0.29 Board and Market Cap. C$33M 15% Management Capital Structure Issued & Outstanding 114.4M Options 7.0M Warrants 722k Public 85% 27
Slide 28: Thank you
Thank you BIOCOMPATIBLE GNR David Regan GOLD NANOROD david@sonanano.com TECHNOLOGY CEO +1 902 448 1416 Sona Nanotech Inc. sonanano.com 28 CSE: SONA | OTCQB: SNANF